Suppr超能文献

HIV-1 包膜高甘露糖补丁的抗体反应。

Antibody responses to the HIV-1 envelope high mannose patch.

机构信息

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States; Department of Medicine, Duke University School of Medicine, Durham, NC, United States.

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, United States; Department of Surgery, Duke University School of Medicine, Durham, NC, United States; Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, United States; Department of Immunology, Duke University School of Medicine, Durham, NC, United States.

出版信息

Adv Immunol. 2019;143:11-73. doi: 10.1016/bs.ai.2019.08.002. Epub 2019 Sep 11.

Abstract

Neutralizing antibodies against human immunodeficiency virus subtype 1 (HIV-1) bind to its envelope glycoprotein (Env). Half of the molecular mass of Env is carbohydrate making it one of the most heavily glycosylated proteins known in nature. HIV-1 Env glycans are derived from the host and present a formidable challenge for host anti-glycan antibody induction. Anti-glycan antibody induction is challenging because anti-HIV-1 glycan antibodies should recognize Env antigen while not acquiring autoreactivity. Thus, the glycan network on HIV-1 Env is referred to as the glycan shield. Despite the challenges presented by immune recognition of host-derived glycans, neutralizing antibodies capable of binding the glycans on HIV-1 Env can be generated by the host immune system in the setting of HIV-1 infection. In particular, a cluster of high mannose glycans, including an N-linked glycan at position 332, form the high mannose patch and are targeted by a variety of broadly neutralizing antibodies. These high mannose patch-directed HIV-1 antibodies can be categorized into distinct categories based on their antibody paratope structure, neutralization activity, and glycan and peptide reactivity. Below we will compare and contrast each of these classes of HIV-1 glycan-dependent antibodies and describe vaccine design efforts to elicit each of these antibody types.

摘要

针对人类免疫缺陷病毒 1 型 (HIV-1) 的中和抗体与包膜糖蛋白 (Env) 结合。Env 的一半分子量是碳水化合物,使其成为自然界中已知的最具糖基化的蛋白质之一。HIV-1 Env 糖基来源于宿主,这对宿主抗糖基抗体的诱导构成了巨大挑战。诱导抗糖基抗体具有挑战性,因为抗 HIV-1 糖基抗体应识别 Env 抗原而不产生自身反应性。因此,HIV-1 Env 上的糖基网络被称为糖基屏蔽。尽管宿主衍生糖基的免疫识别存在挑战,但在 HIV-1 感染的情况下,宿主免疫系统能够产生能够结合 HIV-1 Env 上糖基的中和抗体。特别是,一组高甘露糖糖基,包括位置 332 处的 N 连接糖基,形成高甘露糖斑块,并被多种广泛中和抗体靶向。这些高甘露糖斑块定向的 HIV-1 抗体可以根据其抗体变构区结构、中和活性以及糖基和肽反应性进行分类。下面我们将比较和对比每种 HIV-1 糖基依赖性抗体,并描述引发每种抗体类型的疫苗设计工作。

相似文献

1
Antibody responses to the HIV-1 envelope high mannose patch.HIV-1 包膜高甘露糖补丁的抗体反应。
Adv Immunol. 2019;143:11-73. doi: 10.1016/bs.ai.2019.08.002. Epub 2019 Sep 11.

引用本文的文献

4
The Question of HIV Vaccine: Why Is a Solution Not Yet Available?HIV 疫苗问题:为什么尚未找到解决方案?
J Immunol Res. 2024 Apr 8;2024:2147912. doi: 10.1155/2024/2147912. eCollection 2024.
7
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.诱导广泛中和抗体的 HIV-1 疫苗策略。
Nat Rev Immunol. 2023 Mar;23(3):142-158. doi: 10.1038/s41577-022-00753-w. Epub 2022 Aug 12.

本文引用的文献

7
HIV "shock and kill" therapy: In need of revision.HIV“休克与清除”疗法:需要修订。
Antiviral Res. 2019 Jun;166:19-34. doi: 10.1016/j.antiviral.2019.03.008. Epub 2019 Mar 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验